COLORADO SPRINGS, Colo.,
Nov. 21, 2013 /PRNewswire/ --
Cannabis Science, Inc., (NASDAQ OTC: CBIS) a U.S. Company
specializing in cannabis formulation-based drug development,
announces the signing of a broad licensing agreement with strategic
partner Endocan Corporation (NASDAQ OTC: ENDO) to use patent
N2010968, entitled "Composition for the Treatment of
Neurobehavioral Disorders", for Endocan studies, research and
development, and consumer products.
As previously announced, the subject of the patent is
development of cannabinoid-based formulations to treat a variety of
widespread neurobehavioral conditions, such as attention deficit
hyperactivity disorder (ADHD), anxiety, and sleep disorders.
The products that Endocan intends to produce using the patent will
target substantial international markets that should prove to help
many people in need worldwide. At the same time, Cannabis
Science will be moving forward with research and clinical
development of pharmaceutical grade drugs via the patent.
"We are very excited with the quick movement in reaching a
mutually-beneficial agreement with Endocan Corporation regarding
the use of our recently filed patent addressing cannabinoid-based
treatment for various neurobehavioral disorders. Both of
these companies have different but synergistic missions and can
together take this intellectual property to the market at multiple
levels," stated Dr. Dorothy Bray,
CEO and Director, Cannabis Science, Inc.
Cannabis Science's IP strategy includes developing, owning, and
licensing patents for the Company's proprietary drug development
operations and collaborations with other industry actors to most
effectively help patients.
About Cannabis Science, Inc.
Cannabis Science, Inc. takes advantage of its unique
understanding of metabolic processes to provide novel treatment
approaches to a number of illnesses for which current treatments
and understanding remain unsatisfactory. Cannabinoids have an
extensive history dating back thousands of years, and currently
there are a growing number of peer-reviewed scientific publications
that document the underlying biochemical pathways that cannabinoids
modulate. The Company works with leading experts in drug
development, medicinal characterization, and clinical research to
develop, produce, and commercialize novel therapeutic approaches
for the treatment for illnesses caused by infections as well as for
age-related illness. Our initial focus is on skin cancers and HIV
related cancers such as Kaposi's sarcoma.
Forward Looking Statements
This Press Release includes forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Act of 1934. A statement containing
works such as "anticipate," "seek," intend," "believe," "estimate,"
"expect," "project," "plan," or similar phrases may be deemed
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. Some or all of the events
or results anticipated by these forward-looking statements may not
occur. Factors that could cause or contribute to such differences
include the future U.S. and global economies, the impact of
competition, and the Company's reliance on existing regulations
regarding the use and development of cannabis-based drugs. Cannabis
Science, Inc. does not undertake any duty nor does it intend to
update the results of these forward-looking statements.
Cannabis Science, Inc.
Dr. Dorothy Bray, CEO &
Director
www.cannabisscience.com
Investment Inquiries
Robert Kane, CFO & Director
rkane@cannabisscience.com
561.420.4824
SOURCE Cannabis Science, Inc.; Endocan Corporation